How much is your chain’s counter worth?

Patients who leave without the recommendation they would have accepted. Products missing when they come for them. At a 2–5% net margin, every point of ticket and every avoided stock-out is gold. Measure it now.

10–15% revenue lift from personalization (McKinsey)
10% stock-out rate at large chains (ECR Brasil)
+110% growth in non-pharma categories over 5 years at leading chains (Abrafarma)
Step 1 · Your chain in four numbers

The calculator

Ballpark numbers are fine — enough to see the order of magnitude. Everything runs in your browser; we store nothing until you say so.

Your chain’s numbers

stores
References: Abrafarma chains ~300 · Farmacias Guadalajara ~760. 300
80 800
References: Fragua ~USD 8 · RD Saúde ~USD 24. USD 14
USD 5 USD 40
OTC, dermocosmetics and convenience. Rx is excluded by regulation. Abrafarma chains: 35–45%. 40%
20% 60%
Scenario Ticket uplift in addressable categories (McKinsey measures 10–15%) + stock-out points recovered (0.5 / 1 / 1.5).

Estimated trapped value

USD 3.2M

of added contribution per year, at gross margin, with a ticket uplift of +5% in addressable categories

Missions & adherence USD 1.2M
Bundles & add-ons USD 966k
Avoided stock-outs USD 1.1M
5.9x ROI on Farmatio’s estimated fee
1 month base-fee payback
USD 307M annual chain sales

Estimates based on public benchmarks (Abrafarma / IQVIA, McKinsey, ECR Brasil). 35% gross margin on addressable categories. The split across the three levers is a model assumption. Your real number is measured against control stores — that’s what the report does.

Step 2 · Your personalized report

Turn the estimate into a signable business case

Within 48 hours we’ll send a report with your full simulation:

  • Your chain’s value waterfall, from gross to net value
  • Ticket and mix benchmark vs. the leaders in your country
  • All three scenarios with month-by-month payback
  • Regulatory map of what can be recommended in your country

Your role (optional)

We use your data only to send the report and follow up on this topic. No spam, no shared lists.

Done! We got your simulation. Your personalized report lands within 48 hours. Want to talk sooner: discovery@farmatio.com
10–15% revenue lift from personalization (McKinsey)
10% stock-out rate at large chains (ECR Brasil)
+110% growth in non-pharma categories over 5 years (Abrafarma)
Why you can trust the number

Public benchmarks, not promises

Personalization: 10–15% revenue lift (McKinsey). Stock-outs: ~10% at large chains, and every point recovered is worth 0.5–1% of sales (ECR Brasil). Mix and traffic: Abrafarma / IQVIA, RD Saúde and Fragua.

Only what regulation allows

We exclude prescription-drug sales: we only count OTC, dermocosmetics and convenience, where recommending and promoting is allowed. That’s why the uplift applies to 40%, not 100%.

The fee is paid out of value created

Farmatio charges a base fee per store plus a variable on incremental margin verified against control stores. If the uplift isn’t there, the variable isn’t charged.